Austin Health

Title
Eph Receptors in Cancer.
Publication Date
2023-01-23
Author(s)
Arora, Sakshi
Scott, Andrew M
Janes, Peter W
Subject
Eph receptor
cancer biology
ephrin
receptor tyrosine kinase
targeted therapy
Type of document
Journal Article
OrcId
0000-0002-1296-9447
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0002-9039-1097
DOI
10.3390/biomedicines11020315
Abstract
Eph receptor tyrosine kinases play critical functions during development, in the formation of tissue and organ borders, and the vascular and neural systems. Uniquely among tyrosine kinases, their activities are controlled by binding to membrane-bound ligands, called ephrins. Ephs and ephrins generally have a low expression in adults, functioning mainly in tissue homeostasis and plasticity, but are often overexpressed in cancers, where they are especially associated with undifferentiated or progenitor cells, and with tumour development, vasculature, and invasion. Mutations in Eph receptors also occur in various tumour types and are suspected to promote tumourigenesis. Ephs and ephrins have the capacity to operate as both tumour promoters and tumour suppressors, depending on the circumstances. They have been demonstrated to impact tumour cell proliferation, migration, and invasion in vitro, as well as tumour development, angiogenesis, and metastases in vivo, making them potential therapeutic targets. However, successful development of therapies will require detailed understanding of the opposing roles of Ephs in various cancers. In this review, we discuss the variations in Eph expression and functions in a variety of malignancies. We also describe the multiple strategies that are currently available to target them in tumours, including preclinical and clinical development.
Link
Citation
Biomedicines 2023
Jornal Title
Biomedicines

Files:

NameSizeformatDescriptionLink